left-arrow right-arrow pinterest facebook google_plus linkedin

NRG BR004

Status:

Recruiting | Phase III

Official Title:

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Study Purpose:

The purpose of this study is to compare the usual treatment plus placebo to the usual treatment plus Atezolizumab.

Interventions:

  • Group 1: Treated with paclitaxel, trastuzumab, pertuzumab, and placebo
  • Group 2: Treated with paclitaxel, trastuzumab, pertuzumab, and atezolizumab

Key Participation Requirements:

Gender:

Male or Female

Age:

19 years and older

Diagnosis:

Adenocarcinoma of the breast

Eligibility:

HER2- positive breast cancer

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

NRG BR004

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!